bioAffinity Technologies, Inc. (NASDAQ:BIAF) — Market Cap & Net Worth
Market Cap & Net Worth: bioAffinity Technologies, Inc. (BIAF)
bioAffinity Technologies, Inc. (NASDAQ:BIAF) has a market capitalization of $17.63 Million ($17.63 Million) as of September 25, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #25582 globally and #5395 in its home market, demonstrating a 46.36% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying bioAffinity Technologies, Inc.'s stock price $7.83 by its total outstanding shares 4498675 (4.50 Million). Also see BIAF current and non-current assets for a full breakdown of the balance sheet.
bioAffinity Technologies, Inc. Market Cap History: 2022 to 2026
bioAffinity Technologies, Inc.'s market capitalization history from 2022 to 2026. Data shows change from $7.20 Million to $35.22 Million (-1.42% CAGR). Also see how efficiently does bioAffinity Technologies, Inc. generate cash for how efficiently the company converts equity into cash flow.
Index Memberships
bioAffinity Technologies, Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.64 Trillion | 0.00% | #722 of 976 |
|
NASDAQ Composite
IXIC
|
$42.16 Trillion | 0.00% | #2367 of 3165 |
Weight: bioAffinity Technologies, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
bioAffinity Technologies, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how bioAffinity Technologies, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check bioAffinity Technologies, Inc. (BIAF) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.86x
bioAffinity Technologies, Inc.'s market cap is 0.86 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $7.20 Million | $4.80K | -$8.15 Million | 1498.62x | N/A |
| 2023 | $6.62 Million | $2.53 Million | -$7.94 Million | 2.61x | N/A |
| 2024 | $4.09 Million | $9.36 Million | -$9.04 Million | 0.44x | N/A |
| 2025 | $5.31 Million | $6.16 Million | -$14.91 Million | 0.86x | N/A |
Competitor Companies of BIAF by Market Capitalization
Companies near bioAffinity Technologies, Inc. in the global market cap rankings as of September 25, 2026. Review bioAffinity Technologies, Inc. tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to bioAffinity Technologies, Inc. by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #89 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #154 globally with a market cap of $158.06 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #464 globally with a market cap of $58.78 Billion USD ( CN¥401.66 Billion CNY).
- Natera Inc (NASDAQ:NTRA): Ranked #577 globally with a market cap of $47.01 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #89 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $678.39 |
| #154 | Danaher Corporation | NYSE:DHR | $158.06 Billion | $223.77 |
| #464 | WuXi AppTec Co Ltd | SHG:603259 | $58.78 Billion | CN¥162.40 |
| #577 | Natera Inc | NASDAQ:NTRA | $47.01 Billion | $408.79 |
bioAffinity Technologies, Inc. Historical Marketcap From 2022 to 2026
Between 2022 and today, bioAffinity Technologies, Inc.'s market cap moved from $7.20 Million to $ 35.22 Million, with a yearly change of -1.42%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $35.22 Million | +563.56% |
| 2025 | $5.31 Million | +29.67% |
| 2024 | $4.09 Million | -38.12% |
| 2023 | $6.62 Million | -8.09% |
| 2022 | $7.20 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 25th, 2026 the market cap of bioAffinity Technologies, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $17.63 Million USD |
| MoneyControl | $17.63 Million USD |
| MarketWatch | $17.63 Million USD |
| marketcap.company | $17.63 Million USD |
| Reuters | $17.63 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology t… Read more